Your search for bevacizumab returned 1 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

News remove
Jenny Ko, PharmD remove

Your search for bevacizumab returned 1 results

Sort Results:

Relevant Recent
ASCO 2011

Axitinib vs. Sorafenib as Second-Line Therapy for mRCC: Results of AXIS Trial

Axitinib demonstrated a significantly longer progression-free survival and higher objective response compared with sorafenib as second-line therapy for metastatic renal cell carcinoma, investigators Brian I. Rini, MD, of the Cleveland Clinic, and colleagues reported at the American Society of Clinical Oncology's 2011 Annual Meeting.